The aim of the Houchen et al. study was to compare real-world outcomes of ENTRESTO vs. angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) therapy, in RAASi-naïve patients with HF and reduced ejection fraction (HFrEF). The outcomes showed that fewer patients with HFrEF initiating treatment with sacubitril/valsartan were re-hospitalised compared with patients treated with ACEi/ARB.¹